10.6084/m9.figshare.6445664
Alberto Batticciotto
Alberto
Batticciotto
Roberto Ravasio
Roberto
Ravasio
Marta Riva
Marta
Riva
Piercarlo Sarzi-Puttini
Piercarlo
Sarzi-Puttini
Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate
Adis Journals
2018
Adalimumab
Biological agents
Certolizumab
Etanercept
Number needed to treat (NNT)
Pharmacoeconomics
Rheumatoid arthritis
Rheumatology
Tocilizumab
2018-06-05 12:55:54
Figure
https://adisjournals.figshare.com/articles/figure/Efficacy_and_Treatment_Costs_of_Monotherapy_with_bDMARDs_in_the_Treatment_of_Rheumatoid_Arthritis_in_Patients_Intolerant_to_or_Inappropriate_to_Continue_Treatment_with_Methotrexate/6445664
<p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s12325-016-0372-z">https://link.springer.com/article/10.1007/s12325-016-0372-z</a></p><p></p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âmailto:adisrapidplus@springer.comâ"><b>adisrapidplus@springer.com</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>• Slide decks</p>
<p>• Videos and animations</p>
<p>• Audio abstracts</p>
<p>• Audio slides</p>